ImmunoScape’s CEO interviewed by Enpoints

October 1, 2022

ImmunoScape’s CEO Choon-Peng Ng is featured in Endpoints. Endpoints highlights ImmunoScape’s $14M funding round, our use of machine learning to discover TCR-T cell therapies focused on solid tumors, and our progress toward the clinic.

You can read the full interview at the link below: